British researchers have identified a new gene that is particularly active in a difficult way to treat breast cancer and thus could help in the search for new treatments.
“Our understanding of the genes that drive the development of stem cells led us to seek consequences when these genes go wrong. BCL11A activity stood out because it is very active in the triple negative cancer. He had all the characteristics of a gene of breast cancer novel “said PentAO Liu, lead author of the Wellcome Trust Sanger Institute.
After combing through 3,000 patients with breast cancer, the team from the Wellcome Trust Sanger Institute found that hyperactive BCL11A gene promotes the development and progression of breast “triple negative” cancer.
The research appears in the journal Nature Communications and was conducted in mice and human cells always new routes to explore specific treatments for this aggressive tumor.
There are many types of breast cancers that respond differently to treatment and have different prognoses.
The increased activity of BCL11A gene is found in about eight out of 10 patients with basal-like breast cancer and is associated with more advanced tumor grade.
“Our studies of genes in human cells BCL11A clearly marked as a new driver for triple negative breast cancers,” said co-first author Walid Khaled.
About one in five patients affected by triple negative breast cancer.
The researchers also showed that BCL11A required for normal development of breast cells and progenitors mother believed that the cells that, when mutated, give rise to basal breast cancer type.
The risk of developing breast cancer and / or ovarian cancer of a woman is much greater if a deleterious mutation in BRCA1 or BRCA2 gene is inherited.